ProCE Banner Activity

CME

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Clinical Thought

Read this commentary covering the most recent key data presented at various 2024 gynecologic cancer conferences. Get expert thoughts on the clinical implications of new data presented for ovarian, endometrial, and cervical cancers.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 25, 2024

Expiration: January 24, 2025

Share

Faculty

Floor J Backes

Floor J Backes, MD

Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Angeles Alvarez Secord

Angeles Alvarez Secord, MD, MHSc

Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Merck Sharp & Dohme, LLC

Seagen Inc.

Target Audience

This program is intended for gynecologic oncologists, medical oncologists, and other healthcare professionals involved in treating gynecologic cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Gynecologic Malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Identify specific populations and associated data-supported barriers to optimal outcomes for patients with gynecologic cancers who are at increased risk for poor prognosis

  • Assess predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility

  • Plan individualized treatment strategies, incorporating novel and emerging therapies and combination strategies as appropriate, for patients with cervical, endometrial, and ovarian cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Floor J Backes, MD

Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Floor J. Backes, MD: consultant/advisor/speaker: AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, GlaxoSmithKline, ImmunoGen, Merck; researcher: AstraZeneca, ImmunoGen, Merck, Natera, Tempus.

Angeles Alvarez Secord, MD, MHSc

Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Angeles Alvarez Secord, MD, MHSc: researcher (paid to institution): AbbVie, Aravive, AstraZeneca, Clovis, Eisai, Ellipses Pharma, GlaxoSmithKline, I-MAB Biopharma, Immunogen, Karyopharm, Merck, Mersana, OncoQuest/Canaria Bio, Roche/Genentech, Seagen, VBL Therapeutics, Zentalis; steering committee: Aravive, Canaria Bio, Hoffmann-La Roche, VBL Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 25, 2024, through January 24, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.